|
| Tuesday, 20 September 2022, 23:50 HKT/SGT | |
| |
|
|
|
Gaithersburg, MD, USA and Suzhou BioBay, China, Sept 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead(TM) platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.
Presentation Details
Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Topics:
-- Creating novel siRNA constructs for cancer treatment
-- Introduction to Sirnaomics' polypeptide nanoparticle delivery system (PNP-IT)
-- Introduction to STP705, Sirnaomics' lead oncology siRNA therapeutic targeting TGF-beta1/COX-2
-- Discussion of novel siRNA therapeutics targeting other oncology indications
Presentation Title: GalAhead(TM) Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
Presentation Topics:
-- Introduction to GalAhead(TM), Sirnaomics' GalNAc-RNAi therapeutic platform
-- Miniaturized RNAi (mxRNA) as a key technological component of the platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead(TM)-based programs
For more information about Sirnaomics' presentation, please visit the event website at https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery.
About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.
CONTACT:
Investor Relations:
Nigel Yip, MBA
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com
US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com
Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com
Topic: Press release summary
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
GMG Delivers Its First Ever Bulk Shipment of THERMAL-XR(R) to Nu Calgon in the USA
June 17, 2026 20:29 HKT/SGT
|
|
|
Truecaller Ads Launches 'Call-to-Cart', a New Commerce Surface Built on the Communication Layer 
June 17, 2026 18:00 HKT/SGT
|
|
|
Hitachi expands its work with OpenAI to accelerate AI-driven modernization and cybersecurity
Wednesday, June 17, 2026 1:54:00 PM
|
|
|
Fujitsu and IBM Japan collaborate on modernization to support enterprise digital transformation
Wednesday, June 17, 2026 1:23:00 PM
|
|
|
Sharp to Introduce AQUOS R11 Smartphone
Wednesday, June 17, 2026 12:59:00 PM
|
|
|
Honda to Begin Supplying Three High-output Models of the eGX Electric Power Unit Series for Commercial-Grade Work Equipment
Wednesday, June 17, 2026 12:44:00 PM
|
|
|
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
Wednesday, June 17, 2026 12:28:00 PM
|
|
|
BAE Systems and NEC Sign MoU to Strengthen Japan's Active Cyber Defence
Wednesday, June 17, 2026 12:10:00 PM
|
|
|
Anime Tokyo Station Early Summer Festival
Wednesday, June 17, 2026 10:00:00 AM
|
|
|
Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia
June 17, 2026 09:21 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
